Myriad Genetics

Myriad Genetics (NASDAQ:MYGN) Price Target Lowered to $17.00 at JPMorgan Chase & Co. - WKRB News | 2/9/2020

… a research note published on Friday, The Fly reports. The brokerage currently has an underweight rating on the stock. MYGN has been the subject of several other reports. Zacks Investment Research raised shares of Myriad Genetics from a hold rating to a buy rating and set a $30.00 price objective for the company in a report on Monday, January 13th. Leerink Swann decreased their price objective on shares of Myriad …

The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Myriad Genetics, Inc., Investors (MYGN) | Business Wire | 2/8/2020

LOS ANGELES- The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Myriad Genetics, Inc., (“Myriad” or the “Company”) (NASDAQ: MYGN ) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. Follow us for updates on Twitter: twitter.com/FRC_LAW . If you own Myriad shares and wish to discuss this matter with us, or …

Follow Myriad Genetics:    

Myriad Genetics CEO Mark Capone Resigns | 2/8/2020

The molecular diagnostics company also delivered an earnings miss, and its stock plunged. Feb 7, 2020 at 1:57PM Author Bio Taylor Carmichael is a former attorney and filmmaker. He’s the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool. Myriad Genetics ( NASDAQ:MYGN ) announced on …

Myriad Genetics (NASDAQ:MYGN) Reaches New 52-Week Low on Analyst Downgrade - Ticker Report | 2/8/2020

… at $20.61, with a volume of 4829917 shares trading hands. The stock had previously closed at $29.29. Several other analysts also recently weighed in on MYGN. Needham & Company LLC began coverage on shares of Myriad Genetics in a research note on Friday, January 3rd. They set a “strong-buy” rating and a $36.00 price target for the company. Leerink Swann decreased their price target on shares of Myriad Genetics from …

Myriad Genetics (NASDAQ:MYGN) Releases Earnings Results, Beats Estimates By $0.01 EPS | Daily Political | 2/8/2020

Myriad Genetics (NASDAQ:MYGN) issued its earnings results on Thursday. The company reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.01, Bloomberg Earnings reports. Myriad Genetics had a positive return on equity of 5.42% and a negative net margin of 3.22%. The business had revenue of $195.10 million during the quarter, compared to analysts’ expectations of $209.61 million. During the same …

Myriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by ValuEngine - Dakota Financial News | 2/8/2020

ValuEngine lowered shares of Myriad Genetics (NASDAQ:MYGN) from a buy rating to a hold rating in a research report sent to investors on Tuesday, ValuEngine reports. A number of other equities research analysts have also weighed in on MYGN. Needham & Company LLC assumed coverage on Myriad Genetics Friday, January 3rd. They issued a strong-buy rating and a $36.00 target price for the company. Piper Jaffray Companies lowered their …

Piper Sandler Trims Myriad Genetics (NASDAQ:MYGN) Target Price to | Daily Political | 2/8/2020

Myriad Genetics (NASDAQ:MYGN) had its price objective trimmed by Piper Sandler from to in a report issued on Friday, The Fly reports.MYGN has been the subject of several other research reports. BidaskClub downgraded Myriad Genetics from a strong-buy rating to a buy rating in a report on Saturday, February 1st. Barclays decreased their price target on Myriad Genetics from $22.00 to $18.00 and set an underweight rating for …

Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Myriad Genetics ( MYGN - Free Report ) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items …

Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates | Zacks | 2/7/2020

… selling, general and administrative (SG&A) expenses to $135.6 million in the reported quarter. Adjusted operating loss was $9 million against adjusted operating profit of $7.1 million in the year-ago quarter. Financial Position Myriad Genetics exited second-quarter of fiscal 2020 with cash and cash equivalents of $81.2 million compared with $89.9 million at the end of the first quarter of fiscal 2020.Cumulative cash flow from operating activities …

Molecular Diagnostics Industry Report, 2020 to 2026 - Analysis by Product, Technology, Application, End-user and Region | Markets Insider | Business Insider | 2/7/2020

… Liquid Biotech USA Lonza Group AG Lucence Diagnostics Lucigen Corporation Luminex Corporation Lunglifeai Mapmygenome MDXHealth Medgenome Menarini Silicon Biosystems Merck KGaA Meridian Bioscience Microgenomics S.r.l. Miltenyi Biotec Mirxes Pte. Ltd. Molbio Diagnostics Pvt. Ltd. Myriad Genetics Nanostics Nanostring Technologies Neogenomics Laboratories, Inc. Nowdiagnostics Nucleix Omega Diagnostics Oncodiag Oncodna Opko Health, Inc. Optigene Limited Orasure Technologies Oxford Gene Technology Pacific Biosciences of California Panagene Pathway Genomics Perkin Elmer, Inc. Personal Genome …

The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns | 2/7/2020

… Holding Corp (NASDAQ: TNXP )( announced stalling of enrollment into a Phase 3 study of experimental drug to treat post-traumatic stress disorder following failed futility analysis) Zosano Pharma Corp (NASDAQ: ZSAN ) Stocks In Focus Myriad Genetics CEO Resigns Following Dismal Q2 Results and Weak Guidance Molecular diagnostic company Myriad Genetics, Inc. (NASDAQ: MYGN ) announced abrupt resignation of its CEO Mark Capone, with immediate effect. The company named CFO Bryan Riggsbee …

Myriad Genetics (NASDAQ:MYGN) Releases Q3 2020 After-Hours Earnings Guidance - WKRB News | 2/7/2020

… estimate of $0.30. The company issued revenue guidance of $172-172 million, compared to the consensus revenue estimate of $201.22 million.Myriad Genetics also updated its FY 2020 After-Hours guidance to 0.45-0.45 EPS. Shares of Myriad Genetics stock traded down $0.24 on Thursday, hitting $29.29. The company’s stock had a trading volume of 1,576,906 shares, compared to its average volume of 713,680. Myriad Genetics has a 52-week low of $20.10 …

Myriad Genetics Exec Capone Resigns, Riggsbee Named Interim CEO | 2/7/2020

Want Xconomy news sent to you daily? Myriad Genetics Exec Capone Resigns, Riggsbee Named Interim CEO Xconomy National — Longtime Myriad Genetics (NASDAQ: MYGN ) president and CEO Mark Capone has resigned. The Salt Lake City-based molecular diagnostic company said Myriad and Capone—who has been with the company for 17 years—mutually agreed it was the right time for a leadership transition. Bryan Riggsbee, Myriad’s chief financial officer, was appointed …

Myriad: Fiscal 2Q Earnings Snapshot | 2/7/2020

SALT LAKE CITY (AP) _ Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $8.3 million in its fiscal second quarter. On a per-share basis, the Salt Lake City-based company said it had a loss of 11 cents. Earnings, adjusted for one-time gains and costs, came to 23 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment …

Myriad Genetics (NASDAQ:MYGN) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS | 2/7/2020

… earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.01, Bloomberg Earnings reports. The business had revenue of $195.10 million during the quarter, compared to analyst estimates of $209.61 million. Myriad Genetics had a positive return on equity of 6.48% and a negative net margin of 1.83%. The company’s revenue was down 10.0% compared to the same quarter last year. During the same period last year …

Myriad Genetics (NASDAQ:MYGN) Updates FY20 Earnings Guidance | 2/7/2020

… a quick ratio of 2.61. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -133.14, a price-to-earnings-growth ratio of 3.36 and a beta of 0.99. Myriad Genetics has a 1-year low of $20.10 and a 1-year high of $48.40. Get Myriad Genetics alerts: Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Thursday, February 6th. The company reported …

Myriad Genetics (NASDAQ:MYGN) Updates Q3 Earnings Guidance | 2/7/2020

… guidance to 0.45-0.45 EPS. Shares of MYGN stock traded down $0.24 during mid-day trading on Thursday, hitting $29.29. 1,665,513 shares of the company’s stock were exchanged, compared to its average volume of 715,608. Myriad Genetics has a fifty-two week low of $20.10 and a fifty-two week high of $48.40. The stock has a 50-day simple moving average of $27.94 and a two-hundred day simple moving …

0.6% Return Seen to Date on SmarTrend Myriad Genetics Call (MYGN) | 2/7/2020

0.6% Return Seen to Date on SmarTrend Myriad Genetics Call (MYGN) 1:14am By David Diaz SmarTrend identified an Uptrend for Myriad Genetics ( NASDAQ:MYGN ) on January 15th, 2020 at $29.32. In approximately 3 weeks, Myriad Genetics has returned 0.61% as of today’s recent price of $29.50. In the past 52 weeks, Myriad Genetics share prices have been bracketed by a low of $15.15 and a high of $33.42 and are …

Myriad Genetics Q2 Revenues Decrease 10 Percent; CEO Mark Capone Steps Down | GenomeWeb | 2/7/2020

staff reporter NEW YORK– Myriad Genetics reported after the close of the market on Thursday that its fiscal second quarter revenues declined 10 percent year over year due to billing issues in its prenatal business. For the three months ended Dec. 31, 2019 the firm reported total revenues of $195.1 million, compared to $216.8 million in the year-ago period and far short of the consensus Wall Street estimate of …

Arizona State Retirement System Has $1.35 Million Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) | 2/7/2020

… recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,605 shares of the company’s stock after selling 37,148 shares during the quarter. Arizona State Retirement System owned about 0.07% of Myriad Genetics worth $1,351,000 as of its most recent filing with the Securities and Exchange Commission. A number of other institutional investors and hedge funds also recently bought and sold shares of the business. New York …

Clinical Research

The American College of Medical Genetics and Genom | 2/5/2020

… benefit from the most up to date evidence when they make the difficult medical decisions associated with genetic testing results. Myriad Genetics is an outlier among large testing laboratories in that it has refused to … of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and …

The American College of Medical Genetics and Genomics Calls on Laboratories to Share Variant Classification Data in Response to Recent Wall Street Journal Article | PR Newswire | 2/4/2020

… benefit from the most up to date evidence when they make the difficult medical decisions associated with genetic testing results. Myriad Genetics is an outlier among large testing laboratories in that it has refused to … of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and …

Mental Health

Boom times for K Street’s biggest firms - POLITICO | 1/22/2020

… Hill Strategy: Remix Etherton and Associates, Inc.: Leidos Inc Faegre Baker Daniels Consulting: Myotonic Dystrophy Foundation Faegre Baker Daniels Consulting: Myriad Genetics, Inc. Faegre Baker Daniels Consulting: Pear Therapeutics Faegre Baker Daniels Consulting: Thermo Fisher … LLC: Pillar College Merchant McIntyre & Associates, LLC: Pine Rest Christian Mental Health Services Merchant McIntyre & Associates, LLC: Roosevelt City, Utah Mercury Public Affairs, LLC: Brooks Bawden Moore, LLC on behalf on Ande Mercury Public Affairs …

GeneSight Test: No Significant Results? Try a Different Research Measure | 1/14/2020

… outcome measure, the company decided to simply re-crunch the data with another measure. Voila! Significance found. In early 2019, Myriad Genetics, makers of the GeneSight Psychotropic test, had the results of a study they … Central. He is a psychologist, author, researcher, and expert in mental health online, and has been writing about online behavior, mental health and psychology issues since 1995. Dr. Grohol has a Master’s degree and doctorate …

Precision Medicine

Synthetic Lethality-based Drugs & Targets World Market, Forecast to 2030 by Type of Molecules, Different Target Indications, Synlet Targets, Route of Administration, and Key Geographical Regions | Financial Buzz | 1/9/2020

… Therapeutics Mitsubishi UFJ Capital Mizuho Capital Moffitt Cancer Center Morgan Noble Morgenthaler Ventures Morphic Therapeutics MPM Capital MS Ventures Mylan Myriad Genetics National Agency for Science and Technology National Cancer Institute National Human Genome Research … SBI Investment Scripps Research Institute Sectoral Asset Management Selvita SEngine Precision Medicine Senhwa Biosciences Sequoia China Shanks Lab Sheba Medical Center Shinsei Capital Partners Sierra Oncology SignalRx Pharmaceuticals Silicon Valley Bank Singapore Ministry of Education …

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening Nasdaq:MYGN | Globe Newswire | 11/11/2019

SALT LAKE CITY, Nov. 11, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Ultrasound in Obstetrics and Gynecology . The key finding is that Prequel without a fetal-fraction threshold achieves high accuracy, while maintaining a low test-failure rate of …

Food and Drug Administration

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tencent, Myriad Genetics, Overstock.com, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 11/14/2019

… reminds investors that class action lawsuits have been commenced on behalf of stockholders of Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN), Overstock.com, Inc. (NASDAQ: OSTK), and Waitr Holdings, Inc. (NASDAQ: WTRH … their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing …

Molecular Diagnostics

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN | Globe Newswire | 11/12/2019

November 11, 2019 18:24 ET Source: Pomerantz LLP NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) and certain of its officers. The class action, filed in United States District Court, for the District of Utah, and indexed under 19-cv-00707, is on behalf of a class consisting of all persons and entities other than …

Diagnostic Tests

Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal Screening Nasdaq:MYGN | Globe Newswire | 11/11/2019

SALT LAKE CITY, Nov. 11, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced that a new study of the Prequel … worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major …

Medicare

Myriad Genetics Presents New Test Data in Autoimmune Segment | Zacks | 11/11/2019

Myriad Genetics Presents New Test Data in Autoimmune Segment Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More … cardiovascular risk prediction score in RA. The study assessed 30,751 Medicare patients with RA with the objective of developing and validating the Vectra CVD score. This predicts the risk for a first CV occurrence, by …

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis | Markets Insider | Business Insider | 11/9/2019

SALT LAKE CITY, Nov. 09, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in precision medicine, announced that its Myriad Autoimmune business unit will present new data on the Vectra test at … 2019. 9:00-11:00 a.m. Location: Poster 2350. This study evaluated 30,751 Medicare patients with RA to develop and validate the Vectra CVD score, which predicts risk for a first cardiovascular (CV) event by combining data from …

Clinical Data

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sundial, electroCore, Tencent, and Myriad Genetics and Encourages Investors to Contact the Firm | Globe Newswire | 11/7/2019

… behalf of stockholders of Sundial Growers, Inc. (NASDAQ: SNDL), electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), and Myriad Genetics, Inc. (NASDAQ: MYGN). Stockholders have until the deadlines below to petition the court … Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use of gammaCore, the Company’s treatment for pain associated with episodic …

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against electroCore, Tencent Music, Myriad Genetics, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/30/2019

… action lawsuits have been commenced on behalf of stockholders of electroCore, Inc. (NASDAQ: ECOR ), Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN), and Waitr Holdings, Inc. (NASDAQ: WTRH). Stockholders have until the … Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use of gammaCore, the Company’s treatment for pain associated with episodic …

American Society of Clinical Oncology

Visiongain Report Offers Transformative Insights on the $21.3bn Precision Cancer Diagnostic Tests Market | Markets Insider | Business Insider | 8/14/2019

… biopsy type. • Profile of the selected leading companies : • Abbott Laboratories • Agilent Technologies, Inc. • bioMerieux SA • Genomic Health, Inc. • Illumina, Inc. • Myriad Genetics, Inc. • Qiagen N.V. • Roche Holding AG • Siemens Healthineers • Thermo Fisher Scientific, Inc. • Analysis … Lung Association American Medical Association American Society for Clinical Pathology American Society of Clinical Oncology Association for Molecular Pathology Bpifrance Centers for Medicare & Medicaid Services Chinese National Medical Products Administration College of American Pathologists Columbia …

ACA

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer | Globe Newswire | 8/7/2019

August 07, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Aug. 07, 2019 (GLOBE NEWSWIRE) – Myriad Genetics , Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced that the … with the U.S. Food and Drug Administration (FDA) to authorize BRACAnalysis CDx as a companion diagnostic test for olaparib in mCRPC patients with germline BRCA mutations. “The PROfound trial confirmed the potential benefits of using …

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019 | Globe Newswire | 8/6/2019

August 06, 2019 16:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Aug. 06, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal … AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or …

Grifols

$18Bn+ Molecular Diagnostics Market Outlook, 2026 - Technological Advancements, Favorable Reimbursements, Investment by Major Players | Globe Newswire | 2/7/2020

Grifols (Spain), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), and Myriad Genetics, Inc. (U.S.) Key Topics Covered …

Molecular Diagnostics Industry Report, 2020 to 2026 - Analysis by Product, Technology, Application, End-user and Region | Markets Insider | Business Insider | 2/7/2020

Grifols ( Spain ), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), and Myriad Genetics, Inc. (U.S.) Key Topics Covered 1 Executive Summary 2 Introduction 3 Market Analysis 3.1 Introduction 3.2 Market Segmentation 3.3 Factors Influencing Market 3.3.1 Drivers and Opportunity 3.3.1.1 Increasing Incidence of Infectious Diseases 3.3.1.2 Rising Incidence of Cancer and Non-Infectious Diseases 3.3.1.3 Technological Advancements 3.3.1.4 Favorable Reimbursements 3.3.1.5 Investment by Major Players 3.3.2 Restraints and Threats 3.3.2.1 Lack of …

Eli Lilly

The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns | 2/7/2020

… Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) Beam Therapeutics Inc (NASDAQ: BEAM ) (IPOed Thursday) ChemoCentryx Inc (NASDAQ: CCXI ) Eli Lilly And Co (NYSE: LLY ) Fulgent Genetics Inc (NASDAQ: FLGT ) Insmed Incorporated (NASDAQ: INSM … futility analysis) Zosano Pharma Corp (NASDAQ: ZSAN ) Stocks In Focus Myriad Genetics CEO Resigns Following Dismal Q2 Results and Weak Guidance Molecular diagnostic company Myriad Genetics, Inc. (NASDAQ: MYGN ) announced abrupt resignation of its CEO …

The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs | 2/6/2020

… Therapeutics Inc (NASDAQ: BTAI ) (announced FDA clearance of IND for BXCL501 to treat opioid withdrawal symptoms) ChemoCentryx Inc (NASDAQ: CCXI ) Eli Lilly And Co (NYSE: LLY ) Insmed Incorporated (NASDAQ: INSM ) Halozyme Therapeutics, Inc. (NASDAQ: HALO … the close) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) (after the close) Myriad Genetics, Inc. (NASDAQ: MYGN ) (after the close) Seattle Genetics, Inc. (NASDAQ: SGEN ) (after the close) Natus Medical Inc (NASDAQ: NTUS ) (after the close) LeMaitre …

Abiomed

The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs | 2/6/2020

… JNCE ) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors. Earnings ABIOMED, Inc. (NASDAQ: ABMD ) (before the market open) Bristol-Myers Squibb Co (NYSE: BMY ) (before … the close) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) (after the close) Myriad Genetics, Inc. (NASDAQ: MYGN ) (after the close) Seattle Genetics, Inc. (NASDAQ: SGEN ) (after the close) Natus Medical Inc (NASDAQ: NTUS ) (after the close) LeMaitre …

The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus | 2/2/2020

… NASDAQ: CSII ) (after the close) Misonix Inc (NASDAQ: MSON ) (after the close) SurModics, Inc. (NASDAQ: SRDX ) (after the close) Thursday ABIOMED, Inc. (NASDAQ: ABMD ) (before the market open) Bristol-Myers Squibb Co (NYSE: BMY ) (before … the close) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) (after the close) Myriad Genetics, Inc. (NASDAQ: MYGN ) (after the close) Seattle Genetics, Inc. (NASDAQ: SGEN ) (after the close) Natus Medical Inc (NASDAQ: NTUS ) (after the close) LeMaitre …

Roche Diagnostics

Molecular Diagnostics Market Share & Global Forecast, By Application, Technology, End User, Regions, Companies | 2/3/2020

… By Regions [United States, Europe (Expect Russia), India, China, Japan, Brazil, South Korea, Mexico, Russia and ROW], Companies (Roche, Abbott, Myriad Genetics, Qiagen, BioMérieux and Others)” provides a complete analysis of Molecular Diagnostics Market. Market … Academic Laboratories 7.2 Clinics and Commercial Laboratories 7.3 Others 8. Roche Diagnostics – Company Analysis 8.1 Merger & Acquisitions 8.2 Sales Analysis 9. Abbott Laboratories – Company Analysis 9.1 Merger & Acquisitions 9.2 Sales Analysis 10. Myriad Genetics – Company …

Liquid Biopsy Market 2020- Top Key Players: Biocept, Qiagen, Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini-Silicon Biosystems, Trovagene, Guardant Health | 1/31/2020

… Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini-Silicon Biosystems, Trovagene, Guardant Health, Mdxhealth, Genomic Health, Raindance Technologies, Thermo Fisher Scientific, and Illumina. This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Liquid Biopsy Market is predicted to grow. It helps in understanding …

Gilead

The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus | 2/2/2020

… the market open) BIO-TECHNE Corp (NASDAQ: TECH ) (before the market open) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) (after the close) Gilead Sciences, Inc. (NASDAQ: GILD ) (after the close) Qiagen NV (NYSE: QGEN ) (after the close … the close) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) (after the close) Myriad Genetics, Inc. (NASDAQ: MYGN ) (after the close) Seattle Genetics, Inc. (NASDAQ: SGEN ) (after the close) Natus Medical Inc (NASDAQ: NTUS ) (after the close) LeMaitre …

Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics, Worldwide, 2014-2019 | Globe Newswire | 1/28/2020

… including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda … Tanabe Pharma Moderna Therapeutics Molnlycke Health Care MorphoSys MSD Multispan Myriad Genetics N-of-One Nanion Nano3D Biosciences NanoString Technologies NantPharma Napo Pharmaceuticals Ncardia Neurexpert Newlink Genetics Newomics New York Center for Nanomedicine Research NGM …

Assurex Health

Indy VC Firm Closes $52 Million Fund To Further Invest In Midwest Tech | Forbes | 1/23/2020

… Assurex Health, which was sold to Myriad Genetics for $307 million, a number that includes milestone earn outs; Detroit-based PeachWorks, which was sold to Beyond; and Indianapolis-based Octiv, which was acquired in 2018 by Conga, a Colorado company specializing in document automation …

Pharmacogenomics (PGx) Market Future Scenario, Growth Predictions and Top Leading Players Abbott Laboratories, Affymetrix Inc., Assurex Health Inc, Astrazeneca, GeneDX, Illumina Inc | 1/13/2020

… Assurex Health, Inc, Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Pathway Genomics, Pfizer, Inc, Qiagen, Inc., Rocheg, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific, Transgenomic, and Inc. The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porter’s five techniques for analyzing the Pharmacogenomics (PGx) Market; it also offers the examination of the global market. To …

Merck

Synthetic Lethality-based Drugs & Targets World Market, Forecast to 2030 by Type of Molecules, Different Target Indications, Synlet Targets, Route of Administration, and Key Geographical Regions | Financial Buzz | 1/9/2020

Merck Ventures Metabomed MetaStat Ministry of Economy and Competitiveness Ministry of Education – Singapore Mission Bay Capital Mission Therapeutics Mitsubishi UFJ Capital Mizuho Capital Moffitt Cancer Center Morgan Noble Morgenthaler Ventures Morphic Therapeutics MPM Capital MS Ventures Mylan Myriad Genetics National Agency for Science and Technology National Cancer Institute National Human Genome Research Institute National Institutes of Health National League Against Cancer National Natural Science Foundation of China National Research Foundation …

Myriad Genetics Test to Identify Cancer Patients Gets FDA Nod | Zacks | 10/28/2019

Myriad Genetics Test to Identify Cancer Patients Gets FDA Nod Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read … side effects.Myriad Genetics announced receiving favorable outcomes from the AstraZeneca/Merck Phase III PROfound study in August 2019. The study met its primary endpoint and demonstrated that men with metastatic castration-resistant prostate (mCRPC) cancer …

GeneSight

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tencent, Myriad Genetics, Overstock.com, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 11/14/2019

… reminds investors that class action lawsuits have been commenced on behalf of stockholders of Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN), Overstock.com, Inc. (NASDAQ: OSTK), and Waitr Holdings, Inc. (NASDAQ: WTRH … its acquisition of Assurex Health, Inc. (“Assurex”). Myriad also acquired GeneSight through this acquisition. On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (“Counsyl”). This acquisition provided Myriad with …

Thermo Fisher

Fulgent Genetics’ Impressive Growth Acceleration Has Further To Run - Fulgent Genetics, Inc. (NASDAQ:FLGT) | Seeking Alpha | 11/12/2019

… Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), QIAGEN N. V. (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), BGI Genomics (CHINA), and Thermo Fisher Scientific Inc. (US). Needless to say, Fulgent isn’t among these, which are an order of magnitude larger ( we featured Illumina not long ago ourselves). But given the increase in billable tests (+272% y/y!), it is making …

Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates - November 5, 2019 - Zacks.com | 11/5/2019

Myriad Genetics, Inc . ( MYGN - Free Report ) reported adjusted earnings per share (EPS) of 8 cents in the first quarter of fiscal 2020, reflecting an 81.4% slash year over year. Adjusted EPS also lagged the Zacks … results this earnings season, are Edwards Lifesciences ( EW - Free Report ) , Thermo Fisher Scientific ( TMO - Free Report ) and ResMed ( RMD - Free Report ) , each carrying a Zacks Rank 2 (Buy). You can see the complete list of …

Abbott Laboratories

Fulgent Genetics’ Impressive Growth Acceleration Has Further To Run - Fulgent Genetics, Inc. (NASDAQ:FLGT) | Seeking Alpha | 11/12/2019

Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Illumina Inc. (US), Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), QIAGEN N. V. (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), BGI Genomics (CHINA), and Thermo Fisher Scientific Inc. (US). Needless to say, Fulgent isn’t among these, which are an order of magnitude larger ( we featured Illumina not long ago ourselves). But given …

The companion diagnostics market is projected to reach 7.3 billion by 2024 from USD 3.5 billion in 2019, at a CAGR of 15.7% | Globe Newswire | 10/8/2019

… Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), and Guardant Health, Inc. (US). Research Coverage: This report analyzes the market for various companion diagnostics and their adoption patterns.It aims at estimating the size and future growth potential of the global companion diagnostics market as well as its …

Zacks Investment Research

Myriad Genetics (NASDAQ:MYGN) Price Target Lowered to $17.00 at JPMorgan Chase & Co. - WKRB News | 2/9/2020

Myriad Genetics (NASDAQ:MYGN) had its price objective trimmed by JPMorgan Chase & Co. from $20.00 to $17.00 in a research note published on Friday, The Fly reports. The brokerage currently has an underweight rating on the stock. MYGN has been the subject of several other reports. Zacks Investment Research raised shares of Myriad Genetics from a hold rating to a buy rating and set a $30.00 price objective for the …

Myriad Genetics (NASDAQ:MYGN) Releases Earnings Results, Beats Estimates By $0.01 EPS | Daily Political | 2/8/2020

Myriad Genetics (NASDAQ:MYGN) issued its earnings results on Thursday. The company reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.01, Bloomberg Earnings reports. Myriad Genetics … rating for the company in a report on Friday. Finally, Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a …

Zacks Equity Research

Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates | Zacks | 2/7/2020

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Myriad Genetics ( MYGN - Free Report ) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items …

Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates | Zacks | 2/7/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Myriad Genetics, Inc . ( MYGN - Free Report ) reported adjusted earnings per share (EPS) of 23 cents in the second quarter of fiscal 2020, down 39.5% year over year. Adjusted EPS also lagged the Zacks Consensus Estimate by 25.8%. Sharp year-over-year decline in revenues …

Morgan Stanley

Myriad Genetics to Present at the 2019 Morgan Stanley Global Healthcare Conference | Markets Insider | Business Insider | 8/30/2019

SALT LAKE CITY, Aug. 30, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 8:35 a.m. EDT on September 10, 2019, in New York City. The presentation will be available to interested parties through a live audio webcast accessible through a link …

Goldman Sachs

U.S. STOCKS ON THE MOVE-Bank stocks, industrials, Macy’s, Tilray - Nasdaq.com | 8/14/2019

Myriad Genetics , down 41.3% Mmtec Inc , down 38.6% Reeds Inc , down 26.8% Bank of America Corp : down 4.8% JPMorgan Chase & Co : down 4% Morgan Stanley : down 3.5% Wells Fargo & Co : down 3.8% Goldman Sachs Group Inc GS.N : down 3.6% Banks tracks worst day in 8 months as U.S. yield curve inverts Macy’s : down 13.5% At near 10-year low on dismal earnings; rattles retail stocks Apple Inc : down 2.2% BofA …

Stocks making the biggest moves premarket: Canada Goose, Tilray, RealReal, Qualcomm, CBS & more | CNBC | 8/14/2019

… Jeff Henderson. Former Cardinal Health CFO Henderson will remain on the board and continue to chair the chipmaker’s audit committee. Myriad Genetics – Myriad reported adjusted quarterly profit of 41 cents per share, missing consensus estimates … The eye-care products company’s stock was rated “buy” at Goldman Sachs, citing strong organic revenue growth, among other factors. Goldman also set a price target of $67 per share compared to yesterday’s close of …

William Blair

U.S. STOCKS ON THE MOVE-Bank stocks, industrials, Macy’s, Tilray - Nasdaq.com | 8/14/2019

… Energy Alternatives Inc , up 61.5% Novavax Inc , up 43.1% Akri Therapeutics Plc , up 30.6% The top three Nasdaq percentage losers: Myriad Genetics , down 41.3% Mmtec Inc , down 38.6% Reeds Inc , down 26.8% Bank of America … Covetrus Inc : down 8.6% There are serious questions around Covetrus - William Blair Portola Pharma : up 1.3% Down after pricing stock offering DelMar Pharma : down 42.1% Plunges to record low on deep-discounted stock deal Adaptive …

U.S. STOCKS ON THE MOVE-Macy’s, Apple, Canada Goose, pharma stocks - Nasdaq.com | 8/14/2019

… 47.7 % Akari Therapeutics Plc , up 31.1 % Novavax Inc , up 30.7 % The top three Nasdaq percentage losers: Mmtec Inc , down 48 % Myriad Genetics , down 42.5 % Reeds Inc , down 26.7 % Macy’s : down 14.4% At near 10-year … Covetrus Inc : down 9.0% There are serious questions around Covetrus - William Blair Portola Pharma : up 1.6% Down after pricing stock offering DelMar Pharma : down 42.7% Plunges to record low on deep-discounted stock deal Adaptive …

Harvard Medical School

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

… to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ … to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Mark H. Pollack, M.D., chief medical officer of Myriad … to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety …

Massachusetts General Hospital

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

… to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ … of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety and Depression Association of America and served as chairman of its Scientific Advisory Board. Dr …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Mark H. Pollack, M.D., chief medical officer of Myriad … of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. He is past president of the Anxiety and Depression Association of America and served as chairman of its Scientific Advisory Board. Dr …

Rush University Medical Center

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

… to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Mark H. Pollack, M.D., chief medical officer of Myriad … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

Rush University Medical Center, Chicago IL

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience | Globe Newswire | 10/21/2019

… to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice October 21, 2019 07:05 ET Source: Myriad Genetics, Inc. SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience Nasdaq:MYGN | Globe Newswire | 10/21/2019

SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Mark H. Pollack, M.D., chief medical officer of Myriad … as professor and chair of the Department of Psychiatry at Rush University Medical Center in Chicago. Prior to Rush, Dr. Pollack was a professor of psychiatry at Harvard Medical School and director of the Center …

UnitedHealthcare

Genetic Tests For Psychiatric Drugs Now Covered By Some Insurers : Shots - Health News : NPR | 10/17/2019

… Myriad Genetics, sell about 375,000 of its psychiatric medicine tests in the 2019 fiscal year, according to Jack Meehan, an industry analyst for Barclays. Myriad reported that it sold $113 million worth of the tests. In addition to UnitedHealthcare’s coverage, Myriad Genetics’ test is covered by Medicare, a regional Blue Cross Blue Shield affiliate, and the insurance network for the grocery chain Kroger, a spokesperson says. Genomind has discussed coverage …

Here’s Why Myriad Genetics Dropped 19.2% in August | Yahoo News | 9/9/2019

What happened Shares of Myriad Genetics (NASDAQ: MYGN) fell more than 19% last month, according to data from S&P Global Market Intelligence . The stock shot out of the gate with a more than 50% gain after it quietly disclosed through a regulatory filing that UnitedHealthcare had agreed to cover the GeneSight Psychotropic test beginning in October. That marked the first major insurer to cover the test, arguably the most …

Bragar Eagel

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tencent, Myriad Genetics, Overstock.com, and Waitr Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 11/14/2019

November 13, 2019 18:33 ET Source: Bragar Eagel & Squire NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Tencent Music Entertainment Group (NYSE: TME), Myriad Genetics, Inc. (NASDAQ: MYGN), Overstock.com, Inc. (NASDAQ: OSTK), and Waitr Holdings, Inc. (NASDAQ: WTRH). Stockholders have until the deadlines below to petition the …

Robert S. Willoughby

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN | Globe Newswire | 11/12/2019

… 2019 18:24 ET Source: Pomerantz LLP NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) and certain of its officers. The … can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include …

Phillip Kim

ROSEN, A LEADING GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of Important Deadline in Securities Class Action – MYGN | Business Wire | 11/10/2019

… Myriad Genetics, Inc. (NASDAQ: MYGN) from September 2, 2016 through August 13, 2019, inclusive (the “Class Period”) of the important November 26, 2019 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Myriad investors under the federal securities laws. To join the Myriad class action, go to http://www.rosenlegal.com/cases-register-1685.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email …

Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 11/7/2019

… Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN ) investors who purchased securities between September 2, 2016 and August 13, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Howard G. Smith

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc. | Globe Newswire | 10/28/2019

October 28, 2019 11:00 ET Source: Law Offices of Howard G. Smith BENSALEM, Pa., Oct. 28, 2019 (GLOBE NEWSWIRE) – Law Offices of Howard G. Smith reminds investors of the upcoming November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN ) securities between September 2, 2016 and August 13, 2019 , inclusive …

Reed Kathrein

MYGN CLASS ACTION REMINDER: Hagens Berman Reminds Myriad Genetics (MYGN) Investors of Securities Fraud Lawsuit, Encourages Investors Who Lost $50,000+ to Contact the Firm | Globe Newswire | 10/8/2019

Call: Reed Kathrein, who is leading the firm’s investigation: (510) 725-3000 MYGN Securities Class Action: According to the Complaint , Defendants misled investors about Myriad Genetics’ GeneSight®, a DNA genotyping test to aid psychotropic drug selection for depressed patients. The Complaint alleges Defendants repeatedly promoted the GeneSight® product, while concealing that GeneSight® lacked evidence or information sufficient to support tests in its current form, including the validity of its purported benefits …

Laurence Rosen

ROSEN, A LEADING LAW FIRM, Reminds Myriad Genetics, Inc. Investors of Important Deadline in Securities Class Action – MYGN | Business Wire | 10/6/2019

… BUSINESS WIRE)–Oct 6, 2019– Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Myriad Genetics, Inc. (NASDAQ:MYGN) from September 2, 2016 through August 13, 2019, inclusive (the … version on businesswire.com : https://www.businesswire.com/news/home/20191006005026/en/ CONTACT: Laurence Rosen, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 …

Brian Schall

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $1 to Contact the Firm - Business Wire | 10/2/2019

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm October 02, 2019 … click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of …

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm – Company Announcement - FT.com | Financial Times | 10/1/2019

… 2019– The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Myriad Genetics , Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN ) for violations of §§10(b) and … click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of …

Colleen Lindholz

Here’s what Kroger stands to gain from its new partnership with Myriad Genetics (KR) | Business Insider | 7/16/2019

… each morning, click here. Grocery store chain Kroger announced it’s teaming up with Salt Lake City-based genetic testing company Myriad Genetics to bring the company’s GeneSight test to select members of Kroger’s employee health … pension costs.” And in a press release , Kroger Health President Colleen Lindholz called depression — which affects over 17 million people in the US — the No. 1 cause of disability and lost productivity in the country …

Kroger partners with Myriad Genetics on genetic testing pilot - MedCity News | 7/14/2019

… PM Shares 0 Kroger Health , the healthcare arm of the grocery store chain, has teamed up with genetic testing company Myriad Genetics , on a pilot meant to help employees receive personalized treatments for depression. The … reach remission after their first antidepressant medication,” Kroger Health President Colleen Lindholz said in a statement. “We are committed to helping people combat this debilitating disease, and we’re proud to launch this pilot program. This …